About Dynavax Technologies
Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company's lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg). Its lead cancer immunotherapy candidate is SD-101, a C Class CpG TLR9 agonist is selected for characteristics optimal for treatment of cancer, including high interferon induction. Its SD-101 clinical program is intended to assess the preliminary efficacy of SD-101 in a range of tumors and in combination with a range of treatments. Its advanced inflammatory disease candidate is AZD1419. Its pipeline of product candidates for cancer immunotherapy includes DV281 and CpG-Nanoparticles, which are in the preclinical stage.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: DVAX
- CUSIP: 26815810
- Previous Close: $4.05
- 50 Day Moving Average: $4.08
- 200 Day Moving Average: $8.24
- 52-Week Range: $38,527,000.00 - $3.20
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.08
- P/E Growth: 0.00
- Market Cap: $156.03M
- Outstanding Shares: 38,527,000
- Beta: 1.94
- Net Margins: -2,650.25%
- Return on Equity: -78.57%
- Return on Assets: -65.94%
Companies Related to Dynavax Technologies:
- Current Ratio: 3.86%
- Quick Ratio: 3.86%
What is Dynavax Technologies' stock symbol?
Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."
Where is Dynavax Technologies' stock going? Where will Dynavax Technologies' stock price be in 2017?
5 brokerages have issued 1-year price objectives for Dynavax Technologies' shares. Their forecasts range from $4.00 to $45.00. On average, they expect Dynavax Technologies' share price to reach $20.17 in the next year.
When will Dynavax Technologies announce their earnings?
Dynavax Technologies is scheduled to release their next quarterly earnings announcement on Monday, March, 6th 2017.
What are analysts saying about Dynavax Technologies stock?
Here are some recent quotes from research analysts about Dynavax Technologies stock:
Cowen and Company analysts commented, "DVAX announced that it will undergo corporate restructuring, resulting in an ~40%." (1/6/2017)
According to Zacks Investment Research, "Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. " (11/28/2016)
Who owns Dynavax Technologies stock?
Dynavax Technologies' stock is owned by many different of institutional and retail investors. Top institutional investors include Federated Investors Inc. PA (9.39%), FMR LLC (3.28%), Franklin Resources Inc. (2.54%), State Street Corp (1.83%), Renaissance Technologies LLC (1.20%) and Vivo Capital LLC (0.93%). Company insiders that own Dynavax Technologies stock include Eddie Gray and Robert Janssen.
Who sold Dynavax Technologies stock? Who is selling Dynavax Technologies stock?
Dynavax Technologies' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, FMR LLC, Allianz Asset Management AG and Royce & Associates LP.
Who bought Dynavax Technologies stock? Who is buying Dynavax Technologies stock?
Dynavax Technologies' stock was bought by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Renaissance Technologies LLC, New Leaf Venture Partners L.L.C., Paulson & CO. Inc., Russell Investments Group Ltd. and Tudor Investment Corp Et Al. Company insiders that have bought Dynavax Technologies stock in the last two years include Eddie Gray and Robert Janssen.
How do I buy Dynavax Technologies stock?
Shares of Dynavax Technologies can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Dynavax Technologies stock cost?
One share of Dynavax Technologies stock can currently be purchased for approximately $4.05.